BioCina
Michael Collins has extensive experience in engineering operations and production supervision within the biotechnology and pharmaceutical industries. Currently serving as Engineering Operations Supervisor at BioCina since October 2021, Michael previously held similar supervisory roles at Pfizer from 2015 to September 2021 and at Hospira from 2004 to 2015. Michael's background includes managing production purification teams, overseeing tech transfer processes, and ensuring compliance with GMP standards through documentation and equipment qualification. Michael holds a Bachelor of Science in Pharmacology from the University of Adelaide, completed between 2001 and 2003.
This person is not in any teams
BioCina
BioCina is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical & commercial manufacturing for the microbial, pDNA and mRNA modalities. BioCina’s first facility in Adelaide, South Australia is a testament to the quality of its work. It has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME’s having an average tenure of 15+ years at the site. BioCina boasts an elite quality record having successfully passed regulatory inspections by the US FDA, EMA and Health Canada. It is licensed by the Australian TGA for cGMP manufacturing of bulk drug substance or active intermediates. Through a partnership with NovaCina, BioCina offers clients a highest-quality fill-and-finish solution. BioCina is proud to have clients globally, including U.S., Europe, and the Asia Pacific. Because BioCina is not a drug developer, it only serves clients' products. As one of the fastest growing companies in the biopharmaceutical industry across Australia, BioCina was awarded the 2024 South Australia “Emerging Business of the Year” award. Learn more at https://biocina.com.